<DOC>
	<DOCNO>NCT01802996</DOCNO>
	<brief_summary>This purpose study evaluate evaluate efficacy Magnesium Isoglycyrrhizinate Injection prevention antineoplastic chemotherapy relate acute liver injury .</brief_summary>
	<brief_title>Evaluate Efficacy Magnesium Isoglycyrrhizinate Prevention Chemotherapy Related Acute Liver Injury</brief_title>
	<detailed_description>Total subject : 2040 , experimental group 1360 patient , control group 680 patient . According study subject receive antineoplastic chemotherapy , subject stratify randomize .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<criteria>1 . Male female age 1875 year ; 2 . Patients malignant tumor accord chemotherapy indication , candidate chemotherapy treatment , disease restrict ; 3 . Accorded follow chemotherapy plan : included cisplatinum , ≥60mg/m2/course ; include oxaliplatin , ≥85mg/m2/course ; include cyclophosphamide , ≥600mg/m2/course ; include gemcitabine , ≥60mg/m2/course ; 4 . ECOG≤2 ; 5 . Estimates survival time≥3 month ; 6 . TBIL≤1.0×ULN , ALT、AST≤1.0×ULN ; blood examination , uronoscopy , stool examination , renal function test electrocardiogram normal ; 7 . Patients apart previous chemotherapy finish 2 week ( include 2 week ) . 1 . Patients partial liver radiotherapy ; 2 . Hepatitis B C virus replication state , patient need antiviral therapy ; 3 . Patients serious heart disease , liver kidney disease , metabolism function disorder ; 4 . Patients combine cellular immune therapy ; 5 . Within 2 week application currently possible application drug ( polyene phosphatidylcholine , reduce glutathione , tiopronin hepatoprotective choleretic drug ) , interference study ; 6 . Pregnancy , patient breast feeding ; 7 . Patients know hypersensitivity Glycyrrhizin ; 8 . Patients participate , participate Clinical study new drug within 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>